Group 1 - Yuheng Pharmaceutical plans to resolve a debt dispute with Qingdao Pusheng Puli Enterprise Management Center regarding the equity transfer payment for Yuheng Biotechnology, which involves a 42.12% stake valued at 117.6 million yuan [1] - Due to Pusheng Puli's failure to pay the agreed amount on time, Yuheng Pharmaceutical initiated legal proceedings in April 2024, which are currently in the execution phase, with no payments received yet [1] - Pusheng Puli intends to transfer 20.64% of its stake in Yuheng Biotechnology to Youpeng Biotechnology (Hainan) Co., Ltd., using the proceeds to settle its debt to Yuheng Pharmaceutical [1] Group 2 - November 4 marks the last conversion day for "Nuitai Convertible Bonds," allowing investors to convert their bonds before market close [1] - After November 4, any unconverted "Nuitai Convertible Bonds" will be forcibly redeemed at a price of 100.36 yuan per bond, potentially leading to losses for investors [1]